FLT3 and acute myeloid leukemia: As a consequence of the clear correlation between AML and mutations in FLT3, therapeutic targeting of FLT3 has been intensely pursued in industry and academia for over two decades (Badar et al., 2015 ▸; Leick & Levis, 2017 ▸).